KYORIN Pharmaceutical Co., Ltd.

News
Contact Us
Sitemap

日本語
English

Site Search

About Kyorin
About Kyorin
KYORIN Holdings, Inc. has merged its wholly owned subsidiary KYORIN Pharmaceutical. Co., Ltd and has changed its trade name to “KYORIN Pharmaceutical. Co., Ltd.” on April 2023.
Investor Relations
Investor Relations
This section provides information on the medium-term business plan, financial and performance results, IR library and stock.
Sustainability
Sustainability
Following our corperate philosophy, Kyorin Group is working to contribute to society’s continuous development and our sustainable growth by fulfilling our social responsibility through we business activities with new drug as our core business.
R&D
R&D
A large number of unmet medical needs are still present in the world. This section provides information on our initiatives for drug discovery, and development pipeline.
- New Drugs: Drug Discovery and Development
- Products Under Development

Site Search

日本語
English

KYORIN Pharmaceutical Co., Ltd.

About Kyorin

Investor Relations

Sustainability

R&D
- New Drugs: Drug Discovery and Development
- Products Under Development

News Release
Contact us
Site Map

News

Top
News
Notice of Reduction of Capital Reserve

Notice of Reduction of Capital Reserve

May 11, 2022

Please see the PDF file below for details.

Notice of Reduction of Capital Reserve [ 220.9 KB ]

Previous Article
Next Article

Archive

2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006

Go to page top Top

KYORIN Pharmaceutical Co., Ltd.Top

About Kyorin

Investor Relations

Sustainability

R&D
- New Drugs: Drug Discovery and Development
- Products Under Development

Handling of personal information
Terms and conditions
Social Media Policy
Recommended environment / Web accessibility

©2023 KYORIN Pharmaceutical Co., Ltd. All Rights Reserved.